Rely on Clinical Experience to Guide Treatment Selection for Primary Cicatricial Alopecias

    December 2012 in “ Drugs & Therapy Perspectives ”
    Image of study
    TLDR Doctors use their experience to choose treatments for scarring hair loss because it's hard to diagnose and treat.
    The document from December 2012 addresses the difficulties in diagnosing and treating primary cicatricial alopecias, which are a group of conditions causing irreversible hair loss and account for 3-7% of hair loss consultations. Due to the lack of distinctive features and molecular markers, treatment is challenging and relies heavily on clinical experience. The article highlights the necessity of early intervention to mitigate the progression of inflammation and scarring, but notes that hair regrowth in scarred areas is unlikely and treatment often fails or relapses. A range of pharmacological treatments are recommended based on a combination of literature review, expert opinion, and personal experience, with surgical options considered for some cases. The treatments are categorized into first-line, second-line, and third-line options, with the selection influenced by potential adverse effects and practical considerations. The document summarizes the characteristics and management strategies for primary cicatricial alopecias as reviewed by Rongioletti and Christana.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 282 results
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 3 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community We need to keep these snake oil companies accountable.

      in Treatment  121 upvotes 5 months ago
      Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

    Similar Research

    5 / 1000+ results